UBS Sets Price Targets for Seven Biotechnology Companies
UBS assigned price targets to seven biotechnology companies, with Neutral or Buy ratings also reported for some of the stocks.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Dow Jones Newswires, citing ratings actions published by Benzinga, reported UBS price targets for several biotechnology companies. The target for BioAge Labs (BIOA) was set at $8.00 a share, with coverage initiated at Neutral. Mineralys Therapeutics (MLYS) received a $29.00 target and a Neutral rating.
For Shattuck Labs (STTK), UBS set a $17.00 target and initiated coverage at Buy. Evommune (EVMN) was assigned an $8.00-a-share target. UBS announced an $89.00 target for Vylor (VYLR) and initiated coverage at Buy.
The targets for Odyssey Therapeutics (ODTX) and Tectonic Therapeutic (TECX) were set at $27.00 and $26.00 a share, respectively. The provided reports did not specify UBS ratings for Evommune, Odyssey Therapeutics or Tectonic Therapeutic.
why it matters
The reports mark new UBS assessments across biotechnology stocks. Fresh coverage and target prices can affect investor attention to individual shares, but the items do not provide information on actual stock-price performance.
instruments
sources
- BioAge Labs Price Target Announced at $8.00/Share by UBS — Dow Jones Newswires, 12 October 2026 at 13:44 UTC
- Mineralys Therapeutics Price Target Announced at $29.00/Share by UBS — Dow Jones Newswires, 12 October 2026 at 13:42 UTC
- Shattuck Labs Price Target Announced at $17.00/Share by UBS — Dow Jones Newswires, 12 October 2026 at 13:41 UTC
- Evommune Price Target Announced at $8.00/Share by UBS — Dow Jones Newswires, 12 October 2026 at 13:39 UTC
- Vylor Price Target Announced at $89.00/Share by UBS — Dow Jones Newswires, 12 October 2026 at 13:55 UTC
- Odyssey Therapeutics Price Target Announced at $27.00/Share by UBS — Dow Jones Newswires, 12 October 2026 at 13:52 UTC
- Tectonic Therapeutic Price Target Announced at $26.00/Share by UBS — Dow Jones Newswires, 12 October 2026 at 13:51 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗